Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
Advances in fibroblast-based cardiac reprogramming in the treatment of heart disease.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jin Yuanyuan, Liu Yuchang, Ge Ao, Yu Yang, Wan Ying, Li Chunhong, Zhang Chunxiang
Аннотация
BACKGROUND: Due to population aging and a wide range of risk factors, coupled with the limited regenerative capacity of the myocardium, the prevention and treatment of cardiovascular diseases remain challenging.
METHODS: This review evaluates cardiac reprogramming as an innovative approach to directly convert fibroblasts into functional cardiomyocytes through genetic or pharmacological means. We focus on its application in myocardial infarction, ischemia-reperfusion injury, and heart failure, and discuss strategies for improving reprogramming efficiency and recent advances in nanomaterial-assisted delivery.
RESULTS: Cardiac reprogramming shows potential in reducing fibrosis and restoring function, with efficiency improved through novel delivery systems and optimized protocols.
CONCLUSION: This technology represents a promising strategy for cardiac regeneration, future work should focus on optimizing reprogramming protocols and developing clinically viable delivery systems to accelerate therapeutic translation.
METHODS: This review evaluates cardiac reprogramming as an innovative approach to directly convert fibroblasts into functional cardiomyocytes through genetic or pharmacological means. We focus on its application in myocardial infarction, ischemia-reperfusion injury, and heart failure, and discuss strategies for improving reprogramming efficiency and recent advances in nanomaterial-assisted delivery.
RESULTS: Cardiac reprogramming shows potential in reducing fibrosis and restoring function, with efficiency improved through novel delivery systems and optimized protocols.
CONCLUSION: This technology represents a promising strategy for cardiac regeneration, future work should focus on optimizing reprogramming protocols and developing clinically viable delivery systems to accelerate therapeutic translation.